{
    "organizations": [],
    "uuid": "31020eeb418d433c226c90a47a89005e108b19ec",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-vertex-says-mid-stage-study-testin/brief-vertex-says-mid-stage-study-testing-pain-relief-drug-met-main-goal-idUSFWN1Q4198",
    "ord_in_thread": 0,
    "title": "BRIEF-Vertex Says Mid Stage Study Testing Pain Relief Drug Met Main Goal",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - Vertex Pharmaceuticals Inc:\n* VERTEX ANNOUNCES TREATMENT WITH THE NAV1.8 INHIBITOR VX-150 SHOWED SIGNIFICANT RELIEF OF ACUTE PAIN IN PHASE 2 STUDY\n* VERTEX PHARMACEUTICALS - VX-150 WAS GENERALLY WELL TOLERATED AND SHOWED STATISTICALLY SIGNIFICANT RELIEF OF ACUTE PAIN COMPARED TO PLACEBO IN STUDY\n* VERTEX PHARMACEUTICALS INC - VERTEX ADVANCES ADDITIONAL NAV1.8 INHIBITOR, VX-128, INTO CLINICAL DEVELOPMENT\n* VERTEX PHARMACEUTICALS INC - THERE WERE NO DISCONTINUATIONS FOR ADVERSE EVENTS IN ANY ARM OF STUDY\n* VERTEX PHARMACEUTICALS INC - STUDY MET ITS PRIMARY ENDPOINT Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-14T22:52:00.000+02:00",
    "crawled": "2018-02-15T20:35:46.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "vertex",
        "pharmaceutical",
        "inc",
        "vertex",
        "announces",
        "treatment",
        "inhibitor",
        "showed",
        "significant",
        "relief",
        "acute",
        "pain",
        "phase",
        "study",
        "vertex",
        "pharmaceutical",
        "generally",
        "well",
        "tolerated",
        "showed",
        "statistically",
        "significant",
        "relief",
        "acute",
        "pain",
        "compared",
        "placebo",
        "study",
        "vertex",
        "pharmaceutical",
        "inc",
        "vertex",
        "advance",
        "additional",
        "inhibitor",
        "clinical",
        "development",
        "vertex",
        "pharmaceutical",
        "inc",
        "discontinuation",
        "adverse",
        "event",
        "arm",
        "study",
        "vertex",
        "pharmaceutical",
        "inc",
        "study",
        "met",
        "primary",
        "endpoint",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}